Turtle Creek Wealth Advisors LLC Raises Holdings in AbbVie Inc. $ABBV

Turtle Creek Wealth Advisors LLC lifted its stake in AbbVie Inc. (NYSE:ABBV) by 33.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,192 shares of the company’s stock after purchasing an additional 3,043 shares during the quarter. Turtle Creek Wealth Advisors LLC’s holdings in AbbVie were worth $2,823,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie during the second quarter worth $26,000. Spurstone Advisory Services LLC acquired a new position in shares of AbbVie in the 2nd quarter valued at $28,000. Financial Gravity Companies Inc. purchased a new position in AbbVie in the 2nd quarter worth $36,000. Delos Wealth Advisors LLC acquired a new stake in AbbVie during the 2nd quarter worth about $39,000. Finally, Bear Mountain Capital Inc. lifted its position in AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after acquiring an additional 173 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ABBV has been the subject of several research analyst reports. Erste Group Bank cut AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Evercore ISI increased their price target on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and increased their price objective for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Finally, Citigroup decreased their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $248.11.

AbbVie Price Performance

ABBV opened at $214.38 on Tuesday. The firm has a fifty day moving average price of $226.72 and a 200 day moving average price of $216.82. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The stock has a market cap of $378.89 billion, a P/E ratio of 162.41, a P/E/G ratio of 0.88 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is currently 524.24%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.